Cost Plus Drugs

From WikiMD's Wellness Encyclopedia

Mark Cuban Cost Plus Drug Company logo

Cost Plus Drugs is a pharmaceutical company founded by Mark Cuban with the aim of providing affordable medications to consumers. The company operates on a cost-plus pricing model, which means that it sells medications at the cost of production plus a fixed percentage markup. This approach is intended to make prescription drugs more accessible and affordable for patients.

History[edit | edit source]

Cost Plus Drugs was established in response to the high cost of prescription medications in the United States. The company was founded by entrepreneur and investor Mark Cuban, who is known for his ownership of the Dallas Mavericks and his role on the television show Shark Tank. The company aims to disrupt the traditional pharmaceutical industry by offering transparent pricing and reducing the financial burden on patients.

Business Model[edit | edit source]

The business model of Cost Plus Drugs is based on a cost-plus pricing strategy. This means that the company sells medications at the cost of production plus a fixed percentage markup. This model contrasts with the traditional pharmaceutical pricing model, which often includes significant markups and rebates that can obscure the true cost of medications.

Cost-Plus Pricing[edit | edit source]

Cost-plus pricing is a pricing strategy where a fixed percentage is added to the cost of producing a product to determine its selling price. In the case of Cost Plus Drugs, this means that the company adds a fixed percentage to the cost of manufacturing and distributing medications. This approach is intended to provide transparency and ensure that patients are not overcharged for their medications.

Impact[edit | edit source]

The introduction of Cost Plus Drugs has the potential to significantly impact the pharmaceutical industry by providing a more affordable alternative to traditional drug pricing models. By offering medications at a lower cost, the company aims to reduce the financial burden on patients and improve access to essential medications.

Related Pages[edit | edit source]

Categories[edit | edit source]

Contributors: Prab R. Tumpati, MD